PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product

Last updated: March 14, 2025
Sponsor: Staci Gruber, Ph.D.
Overall Status: Active - Recruiting

Phase

2

Condition

Chronic Pain

Pain

Treatment

Cannabidiol

Placebo

Clinical Study ID

NCT03984565
2023P001774
  • Ages > 21
  • All Genders

Study Summary

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject has provided informed consent

  • Subject is 21 or older

  • Subject is fluent in English

  • Subject endorses a musculoskeletal chronic pain condition including, but not limitedto, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoidarthritis), bursitis, etc.

Exclusion

Exclusion Criteria:

  • Non-fluent English speakers

  • Estimated IQ < 75

  • A history of head injury or loss of consciousness greater than 5 minutes

  • Currently uses CBD products regularly

  • Female subjects will be excluded if they have a positive urine pregnancy test, aretrying to become pregnant, or are currently breastfeeding

  • Presence of a serious or unstable medical illness, including liver, kidney, orcardiovascular disease (hyper/hypotension, cardiac disorders), or neurologicaldisorder (including seizure disorder)

  • Primary neuropathic pain or cancer-related pain; patients experiencing neuropathicpain secondary to musculoskeletal pain will be allowed to enter the study

  • Disclosure of a genetic polymorphism affecting CYP2C9 function

Study Design

Total Participants: 25
Treatment Group(s): 2
Primary Treatment: Cannabidiol
Phase: 2
Study Start date:
June 27, 2024
Estimated Completion Date:
September 30, 2026

Study Description

Cannabis sativa has been used medicinally to treat a wide range of disorders for thousands of years. Cannabis is comprised of more than 100 cannabinoids, including D9-tetrahydrocannabinol (THC), the major intoxicating constituent, and cannabidiol (CBD), the major non-intoxicating constituent that has a number of potential therapeutic properties. Although a wide range of medical cannabis (MC) and hemp products (containing less than 0.3% THC) are used by consumers for a variety of medical indications, little is known about the direct impact of individual cannabinoids and constituent ratios on the symptoms that cause patients to seek treatment.

Chronic pain is one of the most common indications for MC use, and several studies have yielded compelling data suggesting that MC and its constituents may have analgesic and anti-inflammatory properties, suggesting that cannabinoids may have the potential to treat chronic pain. This investigation will involve a placebo-controlled crossover trial of a hemp-derived high-CBD, low-THC sublingual product in patients with chronic pain; patients will be assessed at baseline and over 69weeks of treatment with CBD or placebo on measures of clinical state, including pain and related symptoms, conventional medication use, and cognition, and provide samples for analysis of inflammatory markers.

Connect with a study center

  • McLean Hospital

    Belmont, Massachusetts 02478
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.